IRADIMED (IRMD) CEO Roger Susi Reports 10b5-1 Stock Sales

Rhea-AI Filing Summary

Roger E. Susi, CEO, President and Chairman of IRADIMED CORP (IRMD), reported sales of common stock on 09/17/2025 under a Rule 10b5-1 trading plan adopted 06/16/2025. The filing shows 3,454 shares sold at a weighted average price of $71.0016 and 1,546 shares sold at a weighted average price of $71.8808, executed in multiple trades with price ranges disclosed. After these dispositions, aggregate beneficial ownership reported across related trusts and accounts totals 2,062,500 shares directly and 2,359,046/2,357,500 shares indirectly as stated, with a disclaimer limiting claimed beneficial ownership. The form is signed 09/18/2025.

Positive

• Sales executed under a Rule 10b5-1 trading plan, which provides pre-arranged trading and enhances defensibility against allegations of opportunistic timing
• Weighted average prices and execution price ranges disclosed, increasing transparency about how the trades were executed

Negative

• Officer/Director sold shares (total 5,000 shares), which investors may view as a signal despite the 10b5-1 plan context

Insights

Financial Analyst

TL;DR: Insider sales were executed under a pre-established 10b5-1 plan; ownership remains concentrated across related trusts.

The reported sales are modest in absolute terms (total 5,000 shares) relative to the large indirect and direct holdings disclosed. Execution under a Rule 10b5-1 plan indicates a pre-arranged schedule, which limits contemporaneous trading inference. The filing includes weighted average prices and price ranges, adding transparency about execution. The reporting person’s disclaimer about beneficial ownership suggests complex family/trust ownership structures remain material to overall control.

Corporate Governance Expert

TL;DR: Transactions follow a documented 10b5-1 plan; related-party holdings and disclaimers merit governance clarity.

Use of a 10b5-1 plan and providing price ranges and weighted averages aligns with good disclosure practice. However, the filing reiterates indirect holdings through multiple trusts and a revocable trust, and includes an explicit disclaimer limiting asserted beneficial ownership. For governance reviewers, those ownership allocations and the ongoing officer/director status are material facts to reconcile with voting and control analyses.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		S(1)		3,454	D	$71.0016(2)	2,359,046(3)	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	09/17/2025		S(1)		1,546	D	$71.8808(4)	2,357,500(3)	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(3)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. This transaction was executed in multiple trades at prices ranging from $70.46 to $71.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

4. This transaction was executed in multiple trades at prices ranging from $71.47 to $72.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	/s/ Roger E. Susi	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did IRMD CEO Roger E. Susi report on Form 4?

The Form 4 reports sales on 09/17/2025 of 3,454 shares at a weighted average price of $71.0016 and 1,546 shares at a weighted average price of $71.8808, executed in multiple trades.

Were the 09/17/2025 sales by Roger E. Susi part of a trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 06/16/2025 as stated in the filing.

How much IRMD stock does Roger E. Susi beneficially own after the reported transactions?

The filing lists various holdings: 2,062,500 shares (direct by Roger E. Susi Revocable Trust) and indirect holdings reported as 2,359,046 and 2,357,500 in related trust accounts, with a disclaimer limiting beneficial ownership assertions.

Did the Form 4 provide execution price ranges for the trades?

Yes. The filing discloses price ranges: $70.46 to $71.45 for one set of trades and $71.47 to $72.27 for the other; weighted average prices are reported.

When was the Form 4 signed?

The Form 4 is signed by Roger E. Susi on 09/18/2025.